Evidence map›Paper›PMID 22707751›Full record

SynthesisAnnals of oncology : official journal of the European Society for Medical Oncology2012

Prognosis of medullary breast cancer: analysis of 13 International Breast Cancer Study Group (IBCSG) trials.

J Huober, S Gelber, A Goldhirsch, A S Coates, G Viale, C Öhlschlegel, K N Price, R D Gelber, M M Regan, B Thürlimann

Open access · bronzeAbstract readMeta-Analysis
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Annals of oncology : official journal of the European Society for Medical Oncology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 84 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 7 institutions in 4 countries.

J HuoberBreast Center, Kantonsspital, St Gallen; Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland. Electronic address: jens.huober@med.uni-duesseldorf.de.
S GelberIBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston; Frontier Science and Technology Research Foundation, Boston, USA.
A GoldhirschDepartment of Medicine, European Institute of Oncology, Milan, Italy; Swiss Center for Breast Health, Sant'Anna Clinics, Lugano-Sorengo, Switzerland.
A S CoatesInternational Breast Cancer Study Group and Australian New Zealand Breast Cancer Trials Group, University of Sydney, Sydney, Australia.
G VialeDivision of Pathology and Laboratory Medicine, IBCSG Central Pathology Office, European Institute of Oncology, University of Milan, Milan, Italy.
C ÖhlschlegelDepartment of Pathology, Kantonsspital, St Gallen, Switzerland; Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland.
K N PriceFrontier Science and Technology Research Foundation, Boston, USA.
R D GelberIBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston; Frontier Science and Technology Research Foundation, Boston, USA; Department of Biostatistics, Harvard School of Public Health, Harvard Medical School.
M M ReganIBCSG Statistical Center, Department of Biostatistics and Computational Biology, Dana-Farber Cancer Institute, Boston; Department of Biostatistics, Harvard School of Public Health, Harvard Medical School.
B ThürlimannBreast Center, Kantonsspital, St Gallen; Swiss Group for Clinical Cancer Research (SAKK), Berne, Switzerland.
Kantonsspital St. Gallen · CHHarvard University · USBreast Center · CHDana-Farber Cancer Institute · USFrontier Science & Technology Research Foundation · USThe University of Sydney · AUUniversity of Milan · IT

Funding

IBCSG STATISTICAL CENTER--A BREAST CANCER STUDY RESOURCEU24CA075362 · NCI · DANA-FARBER CANCER INSTITUTE · PI REGAN, MEREDITH M · 1997 to 2015
$7.5M
NCI NIH HHS CA-75362NCI NIH HHS U24 CA075362
6 · The paper itself

Abstract

backgroundTo evaluate whether medullary breast cancer has a better prognosis compared with invasive ductal tumors.

methodsAmong 12,409 patients, 127 were recorded as invasive medullary tumors and 8096 invasive ductal tumors. Medullary and ductal invasive tumors were compared with regard to stage, age at diagnosis, grade, hormone receptor status, peritumoral vascular invasion, and local and systemic treatment. Pattern of relapse, distant recurrence-free interval (DRFI), and overall survival (OS) were determined for both histological groups. Two cohorts were investigated: a full cohort including the pathologist-determined medullary histology without regard to any other tumor features and a cohort restricted to patients with ER-negative grade 3 tumors.

resultsFourteen-year DRFI and OS percents for medullary tumors (n = 127) and invasive ductal tumors (n = 8096) of the full cohort were 76% and 64% [hazard ratio (HR) 0.52, P = 0.0005] and 66% and 57% (HR = 0.75, P = 0.03), respectively. For the restricted cohort, 14-year DRFI and OS percents for the medullary (n = 47) and invasive ductal tumors (n = 1407) were 89% and 63% (HR 0.24, P = 0.002) and 74% and 54% (HR = 0.55, P = 0.01), respectively. Competing risk analysis for DRFI favored medullary tumors (HR medullary/ductal = 0.32; 95% confidence interval = 0.13-0.78, P = 0.01).

conclusionMedullary tumors have a favorable prognosis compared with invasive ductal tumors.

Indexed as

Breast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, MedullaryErbB ReceptorsFemaleHumansMiddle AgedNeoplasm GradingNeoplasm Recurrence, LocalNeoplasm StagingPrognosisReceptors, EstrogenReceptors, ProgesteroneRisk FactorsSurvival RateTreatment OutcomeErbB ReceptorsReceptors, EstrogenReceptors, Progesterone

Identifiers

PMID22707751
PMCPMC3477879
OpenAlexW2100928326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.